Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$95.08M+74.72%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kevin R. Smith
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 753
- Beta
- 1.58
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 1.42
Financials
Revenue
$95.08M+74.7%Net Income
$-3.85M-211.4%EBITDA
$-559.0K-106.3%Free Cash Flow
$1.03M-85.4%EPS (diluted)
$-0.14-156.0%Shares Outstanding (diluted)
27.05M+27.7%Operating Expenses
$48.37MCash & Debt
$105.54MReturn of Capital
$5.62MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $348.67M | $-22.75M | $-0.85 |
| 2024 | $335.70M | $-35.89M | $-1.52 |
| 2023 | $315.66M | $-102.45M | $-4.42 |
| 2022 | $377.24M | $-83.77M | $-3.67 |
| 2021 | $358.00M | $-6.33M | $-0.28 |
| 2020 | $308.49M | $-5.83M | $-0.27 |
| 2019 | $361.94M | $20.95M | $0.96 |
| 2018 | $358.11M | $51.84M | $2.30 |
| 2017 | $249.44M | $21.00M | $1.02 |
| 2016 | $202.83M | $20.52M | $1.02 |
| 2015 | $159.00M | $11.59M | $0.60 |
| 2014 | $112.54M | $6.83M | $0.33 |
| 2013 | $75.44M | $25.43M | $1.01 |
| 2012 | $48.58M | $564.0K | $-0.36 |
Valuation
INGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (4)
- Newszacks.com·45d ago·Neutral
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
View source ↗ - Newszacks.com·55d ago·Neutral
Should Investors Buy Inogen as Low Valuation Meets Execution Risk? Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
View source ↗ - Newszacks.com·55d ago·Neutral
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
View source ↗ - Newszacks.com·56d ago·Neutral
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.11 per share
Typical surprise +26.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.14 vs $-0.15beat
- Thu, May 7$-0.30 vs $-0.24miss
- Tue, Feb 24$-0.26 vs $-0.36beat
- Wed, Nov 5$-0.20 vs $-0.22beat
- Thu, Aug 7$-0.15 vs $-0.22beat
- Wed, May 7$-0.25 vs $-0.52beat
Estimates and results for INGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INGN officers and directors.
- Bought
- —
- Sold
- $142k
0 trades
2 trades
- Yi Boyer Jennifer Msold
- Yi Boyer Jennifer Msold
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lamar Seeligson Smithhouse · TX21 · disclosed Dec 13, 2018 (23d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.